Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Cipla
Merck
UBS
Baxter
Farmers Insurance
Chinese Patent Office
McKesson
Harvard Business School
Novartis

Generated: October 18, 2017

DrugPatentWatch Database Preview

Oak Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for OAK PHARMS, and when can generic versions of OAK PHARMS drugs launch?

OAK PHARMS has fifteen approved drugs.

There are seven US patents protecting OAK PHARMS drugs on OAK PHARMS drugs in the past three years.

There are sixty-six patent family members on OAK PHARMS drugs in twenty-two countries and twenty-eight supplementary protection certificates in ten countries.

Summary for Applicant: Oak Pharms

International Patents:66
US Patents:7
Tradenames:11
Ingredients:11
NDAs:15
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms
NEMBUTAL SODIUM
pentobarbital sodium
CAPSULE;ORAL084095-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Oak Pharms
NEMBUTAL
pentobarbital sodium
SUPPOSITORY;RECTAL083247-004Jan 25, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Oak Pharms Inc
COSOPT PF
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC202667-001Feb 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Oak Pharms Inc
AZASITE
azithromycin
SOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Oak Pharms Inc
AZASITE
azithromycin
SOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Oak Pharms Inc
ZIOPTAN
tafluprost
SOLUTION/DROPS;OPHTHALMIC202514-001Feb 10, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Oak Pharms Inc
XOPENEX
levalbuterol hydrochloride
SOLUTION;INHALATION020837-002Mar 25, 1999ANRXYesYes► Subscribe► Subscribe ► Subscribe
Oak Pharms
NEMBUTAL
pentobarbital
ELIXIR;ORAL083244-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Oak Pharms Inc
AZASITE
azithromycin
SOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Oak Pharms Inc
XOPENEX
levalbuterol hydrochloride
SOLUTION;INHALATION020837-003Jan 30, 2002ANRXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Oak Pharms

Paragraph IV activity for OAK PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
tafluprost
Ophthalmic Solution0.0015%
ZIOPTAN
2/10/2016
levalbuterol tartrate
Inhalation Aerosol0.045 mg/actuation
XOPENEX
2/27/2012
azithromycin
Ophthalmic Solution1%
AZASITE
3/3/2011
levalbuterol hydrochloride
Inhalation Solution0.0025
XOPENEX
5/23/2006
dorzolamide hydrochloride and timolol maleate
Ophthalmic Solution2%/0.5%
COSOPT
10/11/2005
levalbuterol hydrochloride
Inhalation Solution0.0103%, 0.021% and 0.042%
XOPENEX
6/20/2005

Non-Orange Book Patents for Oak Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,749,970Topical treatment of prevention of ocular infections► Subscribe
5,985,920 Difluoroprostaglandin derivatives and their use► Subscribe
6,699,492 Quinolone carboxylic acid compositions and related methods of treatment► Subscribe
7,732,415Topical treatment or prevention of ocular infections► Subscribe
6,685,958 Quinolone carboxylic acid compositions and related methods of treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Oak Pharms Drugs

Country Document Number Estimated Expiration
Denmark0925789► Subscribe
Spain2172242► Subscribe
European Patent Office1165058► Subscribe
Denmark0850926► Subscribe
Germany69716226► Subscribe
Japan4994569► Subscribe
Hong Kong1041642► Subscribe
Canada2368637► Subscribe
Canada2302379► Subscribe
Germany69825128► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Oak Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
09/010Ireland► SubscribePRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/08/491/001-EU/1/08/491/080 20090116; FIRST REGISTRATION NO/DATE: 58935 01 58935 02 58935 03 58935 04 20081028
C0020France► SubscribePRODUCT NAME: COMBINAISON COMRENANT L’ALISKIREN SOUS FORME DE BAE LIBRE OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, ET L’HYDROCHLOROTHIAZIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/08/491/001 DU 20090116; REGISTRATION NO/DATE AT EEC: 58935 01-04 DU 20081028
C0020France► SubscribePRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
943Luxembourg► Subscribe91943, EXPIRES: 20221222
C0033France► SubscribePRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
C/GB99/043United Kingdom► SubscribePRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
C/GB98/031United Kingdom► SubscribePRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
12/018Ireland► SubscribePRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
C013/2011Ireland► SubscribeSPC013/2011: 20110808, EXPIRES: 20221221
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Dow
Daiichi Sankyo
Chinese Patent Office
Boehringer Ingelheim
QuintilesIMS
Harvard Business School
Accenture
Moodys
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot